Strategic Imperatives for Legacy MedTech Leaders
As the tissue technology market shifts from materials to systems, from products to platforms, and from innovation to outcomes, legacy MedTech companies must undergo not just technical evolution, but strategic transformation. Survival - and leadership - will depend on acting across five key imperatives: 1. Reframe the Business from Product Maker to Solution Integrator What must change: Stop thinking in product categories - start thinking in patient journeys. Legacy firms must evolve from selling wound dressings, matrices, or scaffolds to delivering integrated care solutions that combine therapy, monitoring, and outcome management. Action steps:
- Develop end-to-end offerings that bundle biological products with diagnostics, patient education, and post-acute care pathways.
- Build or acquire digital tools (e.g., AI wound imaging, remote monitoring apps) that plug into care pathways.
- Shift go-to-market language from “features and claims” to “clinical and economic outcomes.”
2. Operationalise Real-World Evidence (RWE) as a Core Capability What must change: Clinical trials are no longer enough. Companies must generate continuous, credible real-world data to meet regulatory, payer, and provider demands. Action steps:
- Build in-house RWE teams that can generate, analyse, and publish data at scale.
- Form post-market study consortia with providers to validate long-term outcomes.
- Create digital infrastructure to collect real-time healing data across multiple settings, including the home.
Example: Organogenesis’ strategy of investing in RWE helped it navigate CMS reimbursement volatility in chronic wound care. 3. Forge Strategic Partnerships Beyond the MedTech Sector What must change: The most transformative innovations will not be built in-house. Future leaders will collaborate across biotechnology, software, AI, diagnostics, and even logistics. Action steps:
- Partner with biotech firms for cell or gene therapy adjacencies.
- Collaborate with AI and imaging start-ups to enhance clinical decision-making.
- Explore co-development agreements with digital health or wearable companies.
- Consider joint ventures with payers or providers for bundled outcome models.
Example: Smith&Nephew’s partnerships with AI start-ups and EHR providers signal a pivot toward being a smart-wound care ecosystem, not just a product supplier. 4. Invest in Platform Thinking and Modularity What must change: Legacy pipelines built for single-use products must be redesigned for modularity and scale. The future is platform-driven - where the same biological or digital core can power multiple indications and settings. Action steps:
- Create modular platforms (e.g., scaffold + cells + sensor) that can be tailored for different use cases: burns, DFUs, surgical wounds, reconstructions.
- Standardise across product lines to enable plug-and-play innovation.
- Design data architectures that integrate across therapies and care stages.
Example: Vericel’s platform approach allows expansion from cartilage repair to other autologous cell therapies with shared infrastructure. 5. Rewire the Culture: From Device-Centric to Data-Literate What must change: Culture must shift from engineering-first to evidence-first - from compliance-focused to outcomes-obsessed. This requires talent, mindset, and metrics evolution. Action steps:
- Hire data scientists, systems biologists, and AI strategists into leadership roles.
- Align incentives around long-term outcomes, not short-term sales.
- Train commercial teams to speak the language of health economics, not just technical specs.
Example: 3M’s integration of Health Information Systems into its MedTech division reflects this evolution in cultural DNA. Legacy MedTech firms will not succeed over the next decade by making better versions of the past products. They will win by thinking systemically, acting cross-functionally, and building ecosystems of care that outperform across clinical, economic, and human dimensions. To lead the future of tissue technology, companies must not just adapt to convergence - they must become engines of it.
The Future Shape of the Market
A decade from now, the tissue technology landscape will be defined not by incremental advances, but by full-scale convergence - of biology, data, and digital infrastructure. Four shifts will reshape the competitive and clinical terrain:
- Personalised Regenerative Therapies Cell-, gene-, and scaffold-based treatments will be tailored to individual biology, tissue type, and comorbidity - moving from off-the-shelf to on-demand healing.
- Closed-Loop Wound Care Systems Smart dressings embedded with biosensors, paired with AI-driven platforms, will deliver real-time diagnostics, automated intervention triggers, and predictive healing analytics - blurring the lines between treatment and monitoring.
- Hybrid Surgical-Biologic Interventions Operating rooms will routinely deploy integrated biologic devices - engineered grafts, living adhesives, and smart implants - delivered alongside precision surgical protocols in trauma, oncology, and complex reconstructions.
- Globalisation of Access and Manufacturing As production scales and costs decline regenerative platforms will expand into emerging markets - bringing advanced wound care to millions currently underserved by conventional therapies.
This future will not belong to the largest players but to the most agile. MedTech firms that are digitally fluent, biologically sophisticated, and clinically aligned will succeed and lead. Those that cling to legacy portfolios or underestimate the speed of market convergence will not survive. The next decade is not just about innovating faster - it is about redefining what it means to innovate in medicine.
Takeaways
The regenerative revolution is no longer speculative - it is here, unfolding in clinics, operating rooms, outpatient centres, and home care settings. What was once visionary science is now viable business, driving clinical outcomes and attracting capital. Tissue technology has moved beyond the laboratory and into the healthcare mainstream - but the rules of success are changing. The next decade will not be defined by who first developed a breakthrough scaffold or patented a novel material. It will be shaped by those who build platforms, integrate disciplines, and deliver outcomes at scale. In a market where biology meets data, and care is increasingly decentralised and value-driven, leadership requires orchestration - not just invention. Standing still is no longer a neutral act. For MedTech companies, complacency is a strategic liability. Firms that continue to operate as product manufacturers will be outpaced by those that position themselves as solution providers, data stewards, and ecosystem enablers. This is a moment of both risk and opportunity. The companies that rise to it - by embracing convergence, investing in real-world evidence, and aligning with clinical and economic value - will not just survive the next wave of change; they will define it.
|